Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E (alpha-tocopherol) has been studied for its potential benefit in supporting or treating arteriosclerosis, primarily due to its antioxidant properties. The scientific rationale is that oxidative modification of low-density lipoprotein (LDL) cholesterol plays a key role in the pathogenesis of atherosclerosis (a major form of arteriosclerosis), and vitamin E, as a fat-soluble antioxidant, could theoretically inhibit this process. Early observational studies suggested an association between higher vitamin E intake and reduced cardiovascular risk. However, large randomized controlled trials, such as the HOPE and the Heart Protection Study, have not demonstrated significant benefit of vitamin E supplementation in reducing cardiovascular events or slowing progression of arteriosclerosis in the general population.

Meta-analyses of clinical trials have generally found no significant reduction in major cardiovascular outcomes with vitamin E supplementation, and some studies have suggested possible harm at high doses. As a result, while the use of vitamin E for arteriosclerosis has a scientific basis and has been widely researched, the strength of evidence supporting its efficacy is weak (rated 2/5 here). Clinical guidelines do not recommend vitamin E supplementation specifically for the prevention or treatment of arteriosclerosis or related cardiovascular diseases in the absence of deficiency.

More about Vitamin E (alpha-tocopherol)
More about Arteriosclerosis

Other ingredients used for Arteriosclerosis

Other health conditions supported by Vitamin E (alpha-tocopherol)

Products containing Vitamin E (alpha-tocopherol)